Metabolically labeled monoclonal antibodies were used to measure the number of determinants per cell for an Epstein-Barr virus (EBV) cell surface antigen (EBVCS) (C. Kintner were present approximately 5 x 105 times per in vitro-transformed cell. Immunoprecipitation followed by electrophoresis in polyacrylamide gels containing sodium dodecyl sulfate indicated that four independent monoclonal antibodies to EBVCS recognized a protein of 47,000 daltons. The identification of EBVCS isolated from EBV-transformed cells grown in tunicamycin demonstrated that the antigen when isolated from cells grown without this drug was glycosylated. Finally, preclearing experiments with monoclonal antibodies to EBVCS or to HLA (class I products of the human major histocompatibility locus) and to ,2-microglobulin indicated that EBVCS is not a major histocompatibility type 1 antigen. Epstein-Barr virus (EBV) induces the expression of one or more antigens, termed EBV cell surface antigen (EBVCS) or B-last-1, on the surface of adult human B-lymphocytes soon after it infects them (8, 14, 20, 21) . In preliminary experiments the antigens recognized by anti-EBVCS antibodies and the anti-B-last-1 antibody appear to be distinct (David ThorleyLawson, personal communication). When established human lymphoid cell lines have been tested, the surface antigen(s) has been detected only on those which carry EBV (8, 14, 16, 19, 21) . The antigen(s) is undetectable on primary human B-lymphocytes, detectable on a small percentage of pokeweed mitogen-induced blasts only after cell sorting (21) , and detectable on some samples of peripheral leukocytes from patients with chronic lymphocytic leukemia (21; our unpublished data). This distribution indicates that EBVCS and B-last-1, although induced by EBV, are probably not encoded by the virus. This antigen(s) is expressed uniformly on EBV-transformed cells and therefore is not the membrane antigen, which is found only on productively infected cells (6) . The EBVCS (B-last-1) antigen(s) is often expressed at diminished levels in Burkitt's lymphoma cell lines (8, 14, 20, 21) and is undetectable in some of them (8, 14) . These latter observations are consistent with the antigen(s) being involved in specific T-cell-mediated cytotoxic responses directed against EBVinfected cells in vivo; that is, EBVCS or B-last-1 is a candidate for the lymphocyte-determined membrane antigen (19) Hybridomas. Four of the five hybridomas that we isolated have been described (8) . The fifth was isolated as described previously (8), but we used SP2/0 as a fusion partner. This hybridoma secretes an immunoglobulin G (IgG) monoclonal antibody. We also used two additional hybridomas not isolated by us, BBM.1 and PA2.6, which secrete antibodies to 32-microglobulin and HLA-A,B,C (class I products of the human major histocompatibility locus), respectively (2) Immunoprecipitation and gel electrophoresis. The immunoprecipitation of antigens from labeled cell extracts and their resolution on SDS-polyacrylamide gels were performed generally as described previously (4) . To remove labeled human immunoglobulin from the cell extracts, a preclearing step was performed. Extracts were incubated with 50 ,ug of affinity-purified rabbit anti-human (Fab')2 antibodies per 2 x 107 cells for 60 min at 0°C and then with 250 ,ul of a 10% suspension of formaldehyde-fixed Staphylococcus aureus for 15 min at 0°C. This suspension was clarified by centrifugation at 30,000 rpm for 30 min. The , the cells were washed three times, a portion was counted to determine the amount bound, the cells were lysed in PBS-0.5% Nonidet P-40, and the antibodies were immunoprecipitated. All of antibodies 2 and 4 and 50% of antibody 5 bound to the cells were recovered in the immunoprecipitates. The preparations of the antibodies used for the experiment (unbound) and those recovered in the immunoprecipitates (bound) were resolved on a 10%'o polyacrylamide gel containing SDS and were detected by fluorography. Molecular mass markers (numbers on left, x 103) were phosphorylase a (94,000 daltons), bovine serum albumin (66,000 daltons), glutamate dehydrogenase (58,000 daltons), ovalbumin (44,000 daltons), and chymotrypsinogen (25,000 daltons). Only signals from IgG heavy chains (55,000 daltons), IgM heavy chains (78,000 daltons), and light chains (25,000 daltons) are found in the bound samples, indicating that the labeled species bound to cells are immunoglobulin molecules. The additional bands (near 25,000 daltons) present in the unbound antibody probably represent immunoglobulin light chains secreted by the fusion partner NS-1 used in the creation of the hybridomas anti-EBVCS 2 and 4. SP2/0, which does not express light chains, was used to create anti-EBVCS 5. The fastest-migrating bands in the unbound lanes are at the pH front of the gel. (11) , and the radioactive species were detected by fluorography and autoradiography (1) .
RESULTS
The monoclonal antibodies to EBVCS antigen are the only available tools to define this antigen. To characterize both the antibodies and the molecules to which they bind, we measured how many of each of the antibodies bind at saturation to several cell lines and which of the antibodies compete with one another for binding. For simplicity of presentation, we shall term the antibodies anti-EBVCS 1 through 5 and term the antigen EBVCS.
Binding of anti-EBVCS to cells. To confirm that it is the labeled antibodies and not contaminants that bind to cells, three different preparations of labeled antibodies were incubated with viable cells, the cells were washed three times and lysed, and the antibodies were immunoprecipitated. Between 50 and 100% of the label bound to the cells was recovered in the immunoprecipitates. The immunoprecipitates and their respective antibody preparations were resolved on SDS-polyacrylamide gels (Fig. 1) . The (Fig. 3) . The (7, 18) . Clone 721-61A°B°was selected from a mutagenized sample of clone 721 to be resistant to anti-HLA-A,B typing antisera plus complement (7). Two additional cell lines (BJAB and RAMOS) which are EBV negative and were established from Burkitt's lymphoma biopsies (9, 12) were tested. b The determinants recognized by the 3H-labeled monoclonal antibodies were on the EBVCS molecule (EBVCS 1 through 5), on the HLA framework (HLA-A,B,C), and on the ,2-microglobulin molecules (,B2-microglobulin). The number of molecules of each 3H-labeled antibody bound at saturation was measured by using antibody preparations with specific activities of 1 x 103 to 5 x 10' cpml,ug. Saturation values were constant over 2-to 10-fold ranges of antibody concentrations and occurred usually when there was a 100-to 1,000-fold excess of unbound to bound antibody. Counts bound to the 106 cells tested ranged between 500 and 50,000 cpm above a background of 20 cpm. Anti-EBVCS antibodies bound to the BJAB and RAMOS cell lines gave counts of less than 200 cpm above background.
c ND, Not determined. Fig. 1 . EBVCS in the gel has an apparent molecular mass of 47,000 daltons. cells ( Fig. 2 and 3 ; Table 1 ). That anti-EBVCS 3 fails to precipitate a solubilized antigen but does bind to living cells may indicate that the determinants to which it binds are lost upon solubilization of the EBVCS antigen.
EBVCS is a glycoprotein. A clone of EBVtransformed cells was propagated in tunicamycin (1 ,ug/ml) for increasing times. Surface proteins of these treated cells were labeled, and extracts were made, immunoprecipitated, resolved on gels, and detected by autoradiography. HLA, a prevalent cell surface glycoprotein (17) , was analyzed in parallel in the same lysates. By 24 h of incubation in tunicamycin, a faster-migrating signal could be observed for both EBVCS and the heavy chain of HLA (Fig.  4) . These signals most likely reflect the synthesis and insertion into the cell membrane of proteins which lack the high-mannose residues whose addition is blocked by tunicamycin (5). The fully glycosylated forms of EBVCS and HLA dimin- , and 48 h. Surface proteins of each sample of cells were labeled with Na125I, solubilized, and immunoprecipitated with a pool of anti-EBVCS 1, 4, and 5 antibodies. The supernatants of these immunoprecipitations were used as sources of HLA, which was immunoprecipitated with a pool of anti-HLA and anti-,2-microglobulin antibodies. The immunoprecipitates were resolved in a 10 to 15% gradient polyacrylamide gel containing SDS. The molecular weight markers were those used in Fig. 1 and cytochrome c (11,500 daltons). Apparent molecular weights (in daltons) are as follows: the fully glycosylated EBVCS, 47,000; the less-glycosylated form which appears in the 5.5-(visible on longer exposures), 24-, and 48-h samples, 44,000; the fully glycosylated heavy chain of HLA, 45,000; the less-glycosylated heavy chain which appears in the 5.5-(visible on longer exposures), 24-, and 48-h samples, 43,000; ,2-microglobulin, 11,000. 94 -. . cyte-determined membrane antigen. These characteristics indicate that it might be a type 1 major histocompatibility antigen; that is, it might be associated with 32-microglobulin and even be a modified form of HLA itself. One piece of evidence against this hypothesis is that anti-EBVCS antibodies bound as well to an HLA-A,B-negative variant cell line, 721-61AMB°, as they did to the HLA-A,B-positive parent, 721 (Table 1) .
To test in a different manner for an association among EBVCS, HLA, and ,B2-microglobulin, we removed from one labeled-cell lysate either We used each of these precleared lysates as a source for the other antigen, which was detected by immunoprecipitation, gel electrophoresis, and autoradiography (Fig. 5) . One portion of the lysate precleared of EBVCS (sup I of Fig. 5 (THL-B1) were labeled with Na125I, solubilized, and divided into two portions. One portion (a-EBVCS = I) was immunoprecipitated with a pool of anti-EBVCS 1, 4, and 5 antibodies. A 500-,g portion of this pool of antibodies, which is 10 times that used in the experiments shown in Fig. 3 and 4 , was used for an extract of 107 cells. A total of 0.6% of the incorporated label was precipitated by this pool. The second portion (a-HLA + a-52 = II) was immunoprecipitated with a pool of anti-HLA and anti-32-microglobulin antibodies. Again 500 ILg of a pool of these antibodies was used, which is 10 times that used in the experiment shown in Fig. 4 . A total of 1.1% of the incorporated label was precipitated by this pool. The supernatants from these two immunoprecipitations were each divided into two portions. One portion of the supernatant precleared of All immunoprecipitates were resolved on a 10 to 15% gradient polyacrylamide gel containing SDS and were visualized by autoradiography. The molecular mass markers were those used in Fig. 4 by a T-cell may be difficult to prevent by the binding of one monoclonal antibody to a site near that surface determinant. The failure of a monoclonal antibody to block T-cell killing, therefore, cannot easily be used to test whether the antigen to which the antibody binds is distinct from the structure recognized by the T-cell (14, 16) .
Four of our five antibodies precipitate a surface protein of approximately 47,000 daltons, as do the other three reported antibodies with similar specificities (14, 16, 20, 21) . In addition, the distribution of the antigens among cell lines, when measured both qualitatively and quantitatively, is similar (Table 1) (8, 14, 16, 20, 21) . However, in preliminary experiments EBVCS and B-last-1 appear to be distinct antigens (David Thorley-Lawson, personal communication).
The EBVCS antigen is a glycoprotein (Fig. 4) ; in the presence of tunicamycin it turns over at the cell surface more than once per 24 h (Fig. 4) . If it turns over at the same rate in the absence of the drug, then EBVCS turns over faster than the generation time of the cell, which is approximately 24 h. This turnover rate indicates that EBVCS is either shed from cells or internalized and catabolized.
The EBVCS antigen is not a type 1 major histocompatibility antigen; that is, it is not detectably associated with P2-microglobulin (Fig.   5 ). In addition, the antigen is not detectably associated with HLA-A,B,C (Fig. 5) . Similar experiments with the adenovirus glycoprotein E3/19K indicate that it is associated with HLA-A,B,C antigens (15) , but no other virus-associated antigens which are candidates for being recognized by cytotoxic T-lymphocytes have been shown to be physically associated with HLA antigens (15) . The only reasons still to suspect that EBVCS may be the lymphocyte-determined membrane antigen are its conspicuous expression on EBV-transformed cells (Table 1) and its reduced expression on Burkitt's lymphoma cell lines (8, 14, 20, 21) .
Recent findings indicate that B-last-1 and perhaps EBVCS, which behaves so similarly, is probably not encoded by EBV and may be specific for a differentiated B-lymphoblast (21) . This assignment, although intriguing, does not yet easily mesh with all of the observations on this antigen(s). An EBV-negative Burkitt's lymphoma cell line, RAMOS, which is a B-cell blast, does not express this antigen (Table 1) but does when infected with EBV (21) . CLL cells are not blasts but do express the antigen (21; our unpublished data). One striking feature of the EBVCS (B-last-1) antigen(s) which is consistent with the assignment is that infection by EBV of human B-cells which do not have detectable levels of this antigen leads to its being expressed as a major cell surface antigen.
